EdgeMode Secures Merger with BlackBerry AIF to Propel High-Performance Computing Expansion and Scales AI Data Center Infrastructure
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in several upcoming investor conferences in May 2025.
The company's leadership team, including CEO Riad Sherif, MD and CFO Sylvia Cheung, will present at four major conferences: Bio€quity Europe in Bruges, Bank of America Healthcare Conference in Las Vegas, H.C. Wainwright Annual BioConnect at Nasdaq in New York, and Stifel Virtual Ophthalmology Forum. One-on-one meetings with investors will be available during these events.
Webcast links for the presentations will be accessible on the Events & Presentation page of the Oculis website under the Investors & Media section.Oculis Holding AG (Nasdaq: OCS), un'azienda biofarmaceutica globale specializzata in malattie oftalmiche e neuro-oftalmiche, ha annunciato la sua partecipazione a diverse conferenze per investitori previste per maggio 2025.
Il team dirigenziale dell'azienda, incluso il CEO Riad Sherif, MD e la CFO Sylvia Cheung, presenterà in quattro importanti conferenze: Bio€quity Europe a Bruges, Bank of America Healthcare Conference a Las Vegas, H.C. Wainwright Annual BioConnect al Nasdaq di New York e Stifel Virtual Ophthalmology Forum. Durante questi eventi saranno disponibili incontri individuali con gli investitori.
I link per la trasmissione in diretta delle presentazioni saranno accessibili nella pagina Eventi e Presentazioni del sito web di Oculis, nella sezione Investitori e Media.
Oculis Holding AG (Nasdaq: OCS), una compañía biofarmacéutica global especializada en enfermedades oftálmicas y neuro-oftálmicas, ha anunciado su participación en varias conferencias para inversores programadas para mayo de 2025.
El equipo directivo de la empresa, incluyendo al CEO Riad Sherif, MD y la CFO Sylvia Cheung, presentará en cuatro conferencias principales: Bio€quity Europe en Brujas, Bank of America Healthcare Conference en Las Vegas, H.C. Wainwright Annual BioConnect en Nasdaq, Nueva York, y Stifel Virtual Ophthalmology Forum. Durante estos eventos estarán disponibles reuniones individuales con inversores.
Los enlaces para la transmisión en vivo de las presentaciones estarán accesibles en la página de Eventos y Presentaciones del sitio web de Oculis, dentro de la sección de Inversores y Medios.
Oculis Holding AG (Nasdaq: OCS)는 안과 및 신경안과 질환을 전문으로 하는 글로벌 생명공학 제약 회사로, 2025년 5월에 예정된 여러 투자자 컨퍼런스에 참여할 것이라고 발표했습니다.
회사의 경영진인 CEO Riad Sherif, MD와 CFO Sylvia Cheung는 Bio€quity Europe(브뤼헤), Bank of America Healthcare Conference(라스베이거스), H.C. Wainwright Annual BioConnect(뉴욕 나스닥), Stifel Virtual Ophthalmology Forum 등 4개의 주요 컨퍼런스에서 발표할 예정입니다. 행사 기간 동안 투자자들과 일대일 미팅도 진행됩니다.
발표 웹캐스트 링크는 Oculis 웹사이트 내 투자자 및 미디어 섹션의 이벤트 및 발표 페이지에서 확인할 수 있습니다.
Oculis Holding AG (Nasdaq : OCS), une entreprise biopharmaceutique mondiale spécialisée dans les maladies ophtalmiques et neuro-ophtalmiques, a annoncé sa participation à plusieurs conférences pour investisseurs prévues en mai 2025.
L'équipe de direction de la société, comprenant le CEO Riad Sherif, MD et la CFO Sylvia Cheung, présentera lors de quatre grandes conférences : Bio€quity Europe à Bruges, Bank of America Healthcare Conference à Las Vegas, H.C. Wainwright Annual BioConnect au Nasdaq de New York, et le Stifel Virtual Ophthalmology Forum. Des réunions individuelles avec les investisseurs seront organisées durant ces événements.
Les liens pour le webcast des présentations seront accessibles sur la page Événements & Présentations du site web d'Oculis, dans la section Investisseurs & Médias.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf ophthalmologische und neuro-ophthalmologische Erkrankungen spezialisiert hat, hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen im Mai 2025 angekündigt.
Das Führungsteam des Unternehmens, darunter CEO Riad Sherif, MD und CFO Sylvia Cheung, wird auf vier großen Konferenzen präsentieren: Bio€quity Europe in Brügge, Bank of America Healthcare Conference in Las Vegas, H.C. Wainwright Annual BioConnect am Nasdaq in New York und Stifel Virtual Ophthalmology Forum. Während dieser Veranstaltungen sind Einzelgespräche mit Investoren möglich.
Webcast-Links zu den Präsentationen sind auf der Seite Events & Präsentationen der Oculis-Website im Bereich Investoren & Medien verfügbar.
- None.
- None.
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
Bio€quity Europe
May 12-14, 2025; Bruges, Belgium
Company update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET
Bank of America Healthcare Conference
May 13-15, 2025; Las Vegas, USA
Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT
H.C. Wainwright Annual BioConnect at Nasdaq
May 20, 2025; New York, USA
Company update by Sylvia Cheung, Chief Financial Officer, on May 20 at 9:30am ET
Stifel Virtual Ophthalmology Forum
May 27, 2025; Virtual
Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 27 at 1pm ET
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.
-ENDS-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
FAQ
When and where will Oculis (OCS) present at Bio€quity Europe 2025?
What conferences will Oculis CFO Sylvia Cheung attend in May 2025?
How can investors access Oculis (OCS) conference presentations?
How can investors schedule one-on-one meetings with Oculis management?
